-
Key Findings of the Phase III POLARGO Study Highlight Pola-R-GEMOX as a Potential New Standard of Care for Transplant-Ineligible Patients丨EHA 2025
Diffuse Large B-cell Lymphoma (DLBCL) is the most common subtype of aggressive non-Hodgkin lymphoma in adults. For patients who are relapsed or refractory after first-line therapy and are not candidates…
-
SURPASS-ET Study Results Released: Ropeginterferon as Second-Line Therapy for High-Risk ET Achieves Dual Breakthrough in Efficacy and Safety丨EHA 2025
At the recently held International Congress of Hematology, treatment advances in the field of Myeloproliferative Neoplasms (MPN) have garnered significant attention. As a classic subtype of MPN, Essential Thrombocythemia (ET) has seen no substantial breakthroughs in its treatment over the past two decades. In a Plenary Presentation, Professor Harry Gill of the University of Hong…
-
Professor David Curtis Elaborates on the Breakthrough Results of the ALLG BM12 CAST Study丨EHA 2025
The 30th European Hematology Association (EHA) Annual Meeting 2025 was grandly held in Milan, Italy, gathering top experts from the global hematology community to discuss and share the latest research progress and cutting-edge technologies in the field. During the Plenary Session, Professor David Curtis from the Australasian Leukaemia and Lymphoma Group (ALLG), on behalf of…
-
Subverting Traditional Concepts: CLL Does Not Originate from a Single Clone; Multiple Independent Minor Clones Plant the “Seeds” Early On丨EHA 2025
The 2025 European Hematology Association (EHA) Annual Meeting was grandly held both online and in person, gathering top experts and cutting-edge research from the global hematology community. At this conference, a revolutionary study on the origin of Chronic Lymphocytic Leukemia (CLL) attracted widespread attention. A research team from Spain, using multi-omics single-cell sequencing technologies, revealed…
-
Professor Jakob Kather Elaborates on the Evolution and Future Prospects of AI in Hematologic Oncology丨EHA 2025
The 2025 European Hematology Association (EHA) Annual Meeting was held in a hybrid format, both online and in-person, gathering top experts and scholars from the global hematology community. The conference focused on the deep integration of cutting-edge technology and clinical practice, with the application of Artificial Intelligence (AI) being one of the core topics. Professor…
-
Professor John Mascarenhas Details Breakthrough Safety and Efficacy Data of INCA33989 in Patients with ET丨EHA 2025
The 2025 European Hematology Association (EHA) Annual Meeting was recently held, bringing together top global experts in the field of hematologic malignancies to discuss the latest research findings and future directions. In the highly anticipated “Late-Breaking Abstract” session, Professor John Mascarenhas from the Icahn School of Medicine at Mount Sinai presented clinical study data on…
-
HCT Frailty Scale Pioneers a New Paradigm in Pre-transplant Assessment: Precisely Predicting Prognosis and Optimizing Patient Management丨EHA 2025
Opportunities and Challenges in Allogeneic Transplantation: The Urgent Need for Precise Assessment Professor Maria Queralt Salas pointed out at the beginning of her report that as a potentially curative therapy,…
-
Professor Shaji Kumar Details the Breakthrough Application of Talquetamab plus Teclistamab in Relapsed/Refractory Multiple Myeloma with Extramedullary
Extramedullary Disease: The “Solid Ice” of Multiple Myeloma Treatment Multiple myeloma is a hematologic malignancy characterized by the abnormal proliferation of plasma cells in the bone marrow. However, when these…
Connecting Medical Expertise through Media